Two Indian drugmakers seek to end trials of Merck’s antiviral drug for moderate COVID-19

Published by

By Shivani Singh, Anuron Kumar Mitra and Neha Arora BENGALURU (Reuters) -Two Indian drugmakers have requested permission to end their late-stage trials on Merck & Co’s experimental antiviral drug molnupiravir in moderate COVID-19 patients. The two Indian drugmakers, Aurobindo Pharma Ltd and MSN Laboratories plan to continue late-stage trails of the drug for those with mild COVID-19, the Indian drug regulator’s expert committee said on Friday. The two companies separately sought permission to end trials in the case of moderate COVID-19 patients after having submitted interim clinical trial data…

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *